A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the comfort of Travatan Z in one eye and Xalatan in the opposite eye in patients with primary open-angle glaucoma or ocular hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00690794

Open-angle Glaucoma Ocular Hypertension

COMPLETED PHASE3

Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN

NCT00798759

Open-angle Glaucoma Ocular Hypertension

COMPLETED PHASE4

Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health

NCT00761319

Open-angle Glaucoma Ocular Hypertension

COMPLETED PHASE3

Effects of Travatan Z and Xalatan on Ocular Surface Health

NCT00708422

Glaucoma Ocular Hypertension

COMPLETED PHASE4

Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health

NCT00892762

Open Angle Glaucoma Ocular Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open-Angle Glaucoma Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Travoprost

Travoprost assigned to one eye, with latanoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.

Group Type EXPERIMENTAL

Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)

Intervention Type DRUG

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.

Latanoprost

Latanoprost assigned to one eye, with travoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.

Group Type ACTIVE_COMPARATOR

Latanoprost ophthalmic solution 0.005% (XALATAN®)

Intervention Type DRUG

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.

Intervention Type DRUG

Latanoprost ophthalmic solution 0.005% (XALATAN®)

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TRAVATAN Z® XALATAN®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older.
* Clinical diagnosis of ocular hypertension, primary open-angle, pigment dispersion, or exfoliation glaucoma in both eyes.
* Best corrected visual acuity of 20/200 Snellen or better in each eye.
* Intraocular pressure within protocol-specified range.

Exclusion Criteria

* Any abnormality preventing reliable applanation tonometry in the study eye(s).
* Any eye conditions or procedures as specified in protocol.
* Progressive retinal or optic nerve disease from any cause.
* Use of contact lenses in the study eye(s).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No